NCT05452005 is a Phase 1 clinical trial of [18F]-αvβ6-BP in Lung Cancer, sponsored by University of California, Davis.

Who is sponsoring NCT05452005?

NCT05452005 is sponsored by University of California, Davis.

What drugs are being tested in NCT05452005?

Interventions in NCT05452005: [18F]-αvβ6-BP.

What condition does NCT05452005 study?

NCT05452005 studies Lung Cancer, Lung Cancer Metastatic, Brain Metastases, Non Small Cell Lung Cancer.

Is NCT05452005 still recruiting?

NCT05452005 is currently recruiting now. Last updated 27 February 2026.

Last reviewed 2026-02-27 · How we verify

NCT05452005

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer

Recruiting now Phase 1 Last updated 27 February 2026

What this trial tests

Phase 1 trial testing [18F]-αvβ6-BP in Lung Cancer in 20 participants. Currently enrolling.

Timeline

13 September 2022

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	University of California, Davis
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	20
Start date	13 September 2022
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across United States

Drugs / interventions tested

[18F]-αvβ6-BP

Conditions studied

Lung Cancer — all drugs for Lung Cancer →
Lung Cancer Metastatic — all drugs for Lung Cancer Metastatic →
Brain Metastases — all drugs for Brain Metastases →
Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →

Sponsor

University of California, Davis

Who can join

18 and older, any sex, with Lung Cancer or Lung Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study investigates fluorine-18-AlphaVBeta6-BP (\[18F\]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that \[18F\]-αvβ6-BP PET/Computed Tomography (CT) is a sensitive tool for disease assessment in patients with metastatic NSCLC, including those with brain metastases.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Metastatic brain tumors: from development to cutting-edge treatment.
Tanzhu G, Chen L, Ning J, Xue W, et al · · 2025 · cited 8× · PMID 39712454 · DOI 10.1002/mco2.70020
Bioengineering and Clinical Translation of Human Lung and its Components.
Derman ID, Singh YP, Saini S, Nagamine M, et al · · 2023 · cited 8× · PMID 36658734 · DOI 10.1002/adbi.202200267

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other University of California, Davis trials

Trials by the same sponsor.

NCT07024498 — Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment · NA · not yet recruiting
NCT07322133 — Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE) · Phase 4 · recruiting
NCT07384767 — Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing · Phase 2 · not yet recruiting
NCT07267494 — Image-Guided Herniorrhaphy Study · NA · not yet recruiting
NCT04614714 — Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants · Phase 2, PHASE3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05452005 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Davis
Last refreshed: 27 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05452005.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing